The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double‐Blind, Randomized Controlled Trial
Abstract
Objective: To evaluate the efficacy, including capacity for inhibition of radiographic progression, and safety of upadacitinib, a JAK 1‐selective inhibitor, as compared to placebo or adalimumab in patients with rheumatoid arthritis (RA) who have experienced an inadequate response to methotrexate (MTX). Methods: In total, 1,629 RA patients with an inadequate response to MTX were randomized (2:2:1) to receive upadacitinib (15 mg once daily), placebo, or adalimumab (40 mg every other week) while continuing to take a stable background dose of MTX. The primary end points were achievement of an American College of Rheumatology 20% (ACR 20) improvement response and a Disease Activity Score in 28 joints using C‐reactive protein level (DAS 28‐CRP) of <2.6 in the upadacitinib group compared to the placebo group at week 12; inhibition of radiographic progression was evaluated at week 26. The study was also designed and powered to test for the noninferiority and superiority of upadacitinib compared to adalimumab, as measured both clinically and functionally. Results: At week 12, both primary end points were met in patients receiving upadacitinib compared to those receiving placebo (P ≤ 0.001). An ACR 20 improvement response was achieved by 71% of patients in the upadacitinib group compared to 36% in the placebo group, and a DAS 28‐CRP score of <2.6 was observed in 29% of patients receiving upadacitinib compared to 6% of patients receiving placebo. Upadacitinib was superior to adalimumab based on the ACR 50 response rate, achievement of a DAS 28‐CRP score of ≤3.2, change in pain severity score, and change in the Health Assessment Questionnaire disability index. At week 26, more patients receiving upadacitinib than those receiving placebo or adalimumab achieved low disease activity or remission (P ≤ 0.001). Radiographic progression was significantly inhibited in patients receiving upadacitinib and was observed in fewer upadacitinib‐treated patients than placebo‐treated patients (P ≤ 0.001). Up to week 26, adverse events (AE s), including serious infections, were comparable between the upadacitinib and adalimumab groups. The proportions of patients with serious AE s and AE s leading to discontinuation were highest in the adalimumab group; the proportions of patients with herpes zoster and those with creatine phosphokinase (CPK) elevations were highest in the upadacitinib group. Three malignancies, 5 major adverse cardiovascular events, and 4 deaths were reported among the groups, but none occurred in patients receiving upadacitinib. Six venous thromboembolic events were reported (1 in the placebo group, 2 in the upadacitinib group, and 3 in the adalimumab group). Conclusion: Upadacitinib was superior to placebo and adalimumab for improving signs, symptoms, and physical function in RA patients who were receiving background MTX. In addition, radiographic progression was significantly inhibited by upadacitinib as compared to placebo. The overall safety profile of upadacitinib was generally similar to that of adalimumab, except for higher rates of herpes zoster and CPK elevations in patients receiving upadacitinib.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Aletaha, D., Neogi, T., Silman, A. J., Funovits, J., Felson, D. T., Bingham, C. O., Birnbaum, N. S., Burmester, G. R., Bykerk, V. P., Cohen, M. D., et al. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27584 · Cited by 9,619
Prevoo, M. L. L., Van'T Hof, M. A., Kuper, H. H., Van Leeuwen, M. A., Van De Putte, L. B. A., & Van Riel, P. L. C. M. (1995) · Arthritis & Rheumatism · doi:10.1002/art.1780380107 · Cited by 6,243
Aletaha, D., Neogi, T., Silman, A. J., Funovits, J., Felson, D. T., Bingham, C. O., Birnbaum, N. S., Burmester, G. R., Bykerk, V. P., Cohen, M. D., et al. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.138461 · Cited by 4,941
Validating the SF-36 health survey questionnaire: new outcome measure for primary care.
Brazier, J. E., Harper, R., Jones, N. M., O'Cathain, A., Thomas, K. J., Usherwood, T., & Westlake, L. (1992) · BMJ · doi:10.1136/bmj.305.6846.160 · Cited by 4,653
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
Singh, J. A., Saag, K. G., Bridges, S. L., Akl, E. A., Bannuru, R. R., Sullivan, M. C., Vaysbrot, E., McNaughton, C., Osani, M., Shmerling, R. H., et al. (2016) · Arthritis & Rheumatology · doi:10.1002/art.39480 · Cited by 2,777
Treating rheumatoid arthritis to target: recommendations of an international task force
Smolen, J. S., Aletaha, D., Bijlsma, J. W. J., Breedveld, F. C., Boumpas, D., Burmester, G., Combe, B., Cutolo, M., de Wit, M., Dougados, M., et al. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.123919 · Cited by 2,100
Smolen, J. S., Landewé, R., Bijlsma, J., Burmester, G., Chatzidionysiou, K., Dougados, M., Nam, J., Ramiro, S., Voshaar, M., van Vollenhoven, R., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210715 · Cited by 2,057
Self-citationKlareskog, L., van der Heijde, D., de Jager, J. P., Gough, A., Kalden, J., Malaise, M., Mola, E. M., Pavelka, K., Sany, J., Settas, L., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15640-7 · Cited by 1,751
The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention
O'Shea, J. J., Schwartz, D. M., Villarino, A. V., Gadina, M., McInnes, I. B., & Laurence, A. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-051113-024537 · Cited by 1,599
The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales.
Fries, J. F., Spitz, P. W., & Young, D. Y. (1982) · PubMed · Cited by 1,318
Keystone, E. C., Kavanaugh, A. F., Sharp, J. T., Tannenbaum, H., Hua, Y., Teoh, L. S., Fischkoff, S. A., & Chartash, E. K. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20217 · Cited by 1,172
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
Singh, J. A., Saag, K. G., Bridges, S. L., Akl, E. A., Bannuru, R. R., Sullivan, M. C., Vaysbrot, E., McNaughton, C., Osani, M., Shmerling, R. H., et al. (2016) · Arthritis Care & Research · doi:10.1002/acr.22783 · Cited by 1,107
Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis
van Vollenhoven, R. F., Fleischmann, R., Cohen, S., Lee, E. B., García Meijide, J. A., Wagner, S., Forejtova, S., Zwillich, S. H., Gruben, D., Koncz, T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112072 · Cited by 945
Self-citationWells, G., Becker, J.-C., Teng, J., Dougados, M., Schiff, M., Smolen, J., Aletaha, D., & van Riel, P. L. C. M. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.084459 · Cited by 878
Baricitinib in Patients with Refractory Rheumatoid Arthritis
Genovese, M. C., Kremer, J., Zamani, O., Ludivico, C., Krogulec, M., Xie, L., Beattie, S. D., Koch, A. E., Cardillo, T. E., Rooney, T. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1507247 · Cited by 627
Self-citationvan der Heijde, D., Tanaka, Y., Fleischmann, R., Keystone, E., Kremer, J., Zerbini, C., Cardiel, M. H., Cohen, S., Nash, P., Song, Y., et al. (2013) · Arthritis & Rheumatism · doi:10.1002/art.37816 · Cited by 577
Self-citationFleischmann, R., Mysler, E., Hall, S., Kivitz, A. J., Moots, R. J., Luo, Z., DeMasi, R., Soma, K., Zhang, R., Takiya, L., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31618-5 · Cited by 499
Self-citationCella, D. F., Yount, S., Sorensen, M., Chartash, E., Sengupta, N., & Grober, J. (2005) · PubMed · Cited by 496
Kremer, J., Li, Z.-G., Hall, S., Fleischmann, R., Genovese, M., Martin-Mola, E., Isaacs, J. D., Gruben, D., Wallenstein, G., Krishnaswami, S., et al. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-4-201308200-00006 · Cited by 448
Self-citationGenovese, M. C., Fleischmann, R., Combe, B., Hall, S., Rubbert-Roth, A., Zhang, Y., Zhou, Y., Mohamed, M.-E. F., Meerwein, S., & Pangan, A. L. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31116-4 · Cited by 422
Self-citationDougados, M., van der Heijde, D., Chen, Y.-C., Greenwald, M., Drescher, E., Liu, J., Beattie, S., Witt, S., de la Torre, I., Gaich, C., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210094 · Cited by 404
Smolen, J. S., Pangan, A. L., Emery, P., Rigby, W., Tanaka, Y., Vargas, J. I., Zhang, Y., Damjanov, N., Friedman, A., Othman, A. A., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30419-2 · Cited by 379
Self-citationBurmester, G. R., Kremer, J. M., Van den Bosch, F., Kivitz, A., Bessette, L., Li, Y., Zhou, Y., Othman, A. A., Pangan, A. L., & Camp, H. S. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31115-2 · Cited by 373
Self-citationNam, J. L., Ramiro, S., Gaujoux-Viala, C., Takase, K., Leon-Garcia, M., Emery, P., Gossec, L., Landewe, R., Smolen, J. S., & Buch, M. H. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204577 · Cited by 354
van der Heijde, D. M., van't Hof, M. A., van Riel, P. L., van Leeuwen, M. A., van Rijswijk, M. H., & van de Putte, L. B. (1992) · Annals of the Rheumatic Diseases · doi:10.1136/ard.51.2.177 · Cited by 325
Heiberg, T., & Kvien, T. K. (2002) · Arthritis Care & Research · doi:10.1002/art.10515 · Cited by 295
Schiff, M., Weinblatt, M. E., Valente, R., van der Heijde, D., Citera, G., Elegbe, A., Maldonado, M., & Fleischmann, R. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-203843 · Cited by 293
Self-citationWesthovens, R., Taylor, P. C., Alten, R., Pavlova, D., Enríquez-Sosa, F., Mazur, M., Greenwald, M., Van der Aa, A., Vanhoutte, F., Tasset, C., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210104 · Cited by 236
van Vollenhoven, R., Takeuchi, T., Pangan, A. L., Friedman, A., Mohamed, M. F., Chen, S., Rischmueller, M., Blanco, R., Xavier, R. M., & Strand, V. (2020) · Arthritis & Rheumatology · doi:10.1002/art.41384 · Cited by 230
Self-citationGenovese, M. C., Smolen, J. S., Weinblatt, M. E., Burmester, G. R., Meerwein, S., Camp, H. S., Wang, L., Othman, A. A., Khan, N., Pangan, A. L., et al. (2016) · Arthritis & Rheumatology · doi:10.1002/art.39808 · Cited by 200
Self-citationCharles‐Schoeman, C., Fleischmann, R., Davignon, J., Schwartz, H., Turner, S. M., Beysen, C., Milad, M., Hellerstein, M. K., Luo, Z., Kaplan, I. V., et al. (2015) · Arthritis & Rheumatology · doi:10.1002/art.38974 · Cited by 188
Self-citationKalden, J. R., & Schulze-Koops, H. (2017) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2017.187 · Cited by 187
Kremer, J. M., Emery, P., Camp, H. S., Friedman, A., Wang, L., Othman, A. A., Khan, N., Pangan, A. L., Jungerwirth, S., & Keystone, E. C. (2016) · Arthritis & Rheumatology · doi:10.1002/art.39801 · Cited by 182
Self-citationSmolen, J. S., Burmester, G.-R., Combe, B., Curtis, J. R., Hall, S., Haraoui, B., van Vollenhoven, R., Cioffi, C., Ecoffet, C., Gervitz, L., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31651-8 · Cited by 181
Self-citationCardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis
Taylor, P. C., Weinblatt, M. E., Burmester, G. R., Rooney, T. P., Witt, S., Walls, C. D., Issa, M., Salinas, C. A., Saifan, C., Zhang, X., et al. (2019) · Arthritis & Rheumatology · doi:10.1002/art.40841 · Cited by 176
Thromboembolism with Janus Kinase (JAK) Inhibitors for Rheumatoid Arthritis: How Real is the Risk?
Scott, I. C., Hider, S., & Scott, D. L. (2018) · Drug Safety · doi:10.1007/s40264-018-0651-5 · Cited by 150
Risk of Venous Thromboembolism in Patients With Rheumatoid Arthritis
Kim, S. C., Schneeweiß, S., Liu, J., & Solomon, D. H. (2013) · Arthritis Care & Research · doi:10.1002/acr.22039 · Cited by 147
Choi, H. K., Rho, Y. H., Zhu, Y., Soriano, L. C., Aviña-Zubieta, J. A., & Zhang, Y. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-201669 · Cited by 141
WOODWORTH, T. G., Furst, D. E., Alten, R., et al. (2007) · PubMed · Cited by 112
Burmester, G. R., Landewé, R., Genovese, M. C., Friedman, A., Pfeifer, N. D., Varothai, N., & Lacerda, A. P. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209322 · Cited by 112
Self-citationSalaffi, F., Giacobazzi, G., & Carlo, M. D. (2018) · Pain Research and Management · doi:10.1155/2018/8564215 · Cited by 92
Methodological and statistical approaches to criteria development in rheumatic diseases
Felson, D. T., & Anderson, J. J. (1995) · Baillière s Clinical Rheumatology · doi:10.1016/s0950-3579(05)80189-x · Cited by 79
Fautrel, B., Granger, B., Combe, B. G., Saraux, A., Guillemin, F., & Loët, X. L. (2012) · Arthritis Research & Therapy · doi:10.1186/ar4092 · Cited by 78
Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies
Taylor, P., Kremer, J., Emery, P., Zuckerman, S., Ruotolo, G., Zhong, J., Chen, L., Witt, S., Saifan, C., Kurzawa, M., et al. (2018) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-212461 · Cited by 57
Mohamed, M. F., Nader, A. M., Winzenborg, I., Doelger, E., Noertersheuser, P. A., Pangan, A. L., & Othman, A. (2019) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-eular.752 · Cited by 2
Self-citation
Cited by
Smolen, J. S., Landewé, R. B. M., Bijlsma, J. W. J., Burmester, G. R., Dougados, M., Kerschbaumer, A., McInnes, I. B., Sepriano, A., van Vollenhoven, R. F., de Wit, M., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-216655 · Cited by 2,710
Self-citationEvolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer
Xue, C., Yao, Q., Gu, X., Shi, Q., Yuan, X., Chu, Q., Bao, Z., Lu, J., & Li, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01468-7 · Cited by 699
Janus kinase-targeting therapies in rheumatology: A mechanisms-based approach
Tanaka, Y., Luo, Y., O’Shea, J. J., & Nakayamada, S. (2022) · Nature Reviews Rheumatology · doi:10.1038/s41584-021-00726-8 · Cited by 501
van der Heijde, D., Song, I.-H., Pangan, A. L., Deodhar, A., van den Bosch, F., Maksymowych, W. P., Kim, T.-H., Kishimoto, M., Everding, A., Sui, Y., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32534-6 · Cited by 357
Self-citationMoving towards personalized treatments of immune-related adverse events
Esfahani, K., Elkrief, A., Calabrese, C., Lapointe, R., Hudson, M., Routy, B., Miller, W. H., & Calabrese, L. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0352-8 · Cited by 351
Metadata
- Authors
- Fleischmann, R., Pangan, A. L., Song, I., Mysler, E., Bessette, L., Peterfy, C., Durez, P., Ostor, A. J., Li, Y., Zhou, Y., Othman, A. A., & Genovese, M. C.
- Venue
- Arthritis & Rheumatology
- Publisher
- Wiley
- Published
- 2019-08-28
- Volume
- 71
- Issue
- 11
- Pages
- 1788-1800
- ISSN
- 2326-5191 (ISSN-L)
- 2326-5205
- OpenAlex
- W2961111920
- Cited by
- 444
- References
- 45
- FWCI
- 36.86
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.